Quarterly revenue remained at $0, reflecting a pre‑commercial stage company. Net loss expanded to $79.2 million (‑$0.52 per ADS), driven by higher R&D expense.

Recursion Pharmaceuticals reported Q1 2026 revenue of $6.47 million, missing estimates, with a net loss of $117.5 million but cash reserves of $665.2 million extending runway into early 2028. Clinical advancements include positive early data for REC-1245 (no dose-limiting toxicities) and REC-4881 (polyp reductions in familial adenomatous polyposis), alongside first dosing in REC-4539.

RGNX shares are down approximately 22% in premarket trading on May 14, 2026, despite the company announcing positive topline results from the pivotal Phase III AFFINITY DUCHENNE® trial of RGX-202 for Duchenne muscular dystrophy. Primary catalyst: Q1 2026 revenue collapsed to $6.4 million from $89.0 million in Q1 2025 — a 93% year-over-year decline — driven by the expiration of ZOLGENSMA® patent royalties and the absence of the $70 million Nippon Shinyaku milestone recognized in Q1 2025.

Shares of CAI are declining approximately 14.00% on Wednesday, May 13, 2026, falling from a Tuesday, May 12 close of $18.87 to approximately $16.23 — extending a severe post-earnings selloff wave that has erased more than 30% of CAI's value year-to-date and reflects a persistent valuation compression driven by a cascade of institutional analyst price target reductions that began following the company's Q1 2026 earnings release.

BCAX shares are trading approximately 11% lower in Monday premarket activity, with shares indicated near ~$20.10, compared to Friday's closing price of $22.58. The primary catalyst is Bicara Therapeutics' Q1 2026 earnings report, released before the market opened on May 11, 2026, which revealed a widening net loss of $56.2 million.

Vertex reported Q1 2026 total revenue of $2.99 billion, up 8% year-over-year from $2.77 billion, driven by cystic fibrosis (CF) franchise strength. Non-GAAP diluted EPS (earnings per share) came in at $4.47, surpassing consensus estimates around $4.23-$4.43; GAAP EPS was $4.02.

MapLight Therapeutics ( MPLT ) shares are down 10.59% at $27.44 in today's trading session. Intraday low hit $28.06 amid elevated volatility following recent positive trial news.

Nanobiotix S.A. (NBTX) shares plunged 11.18% to $31.20 during today's trading session from the previous close of $35.12. No specific company news or catalyst triggered the decline; the move appears driven by technical factors and high volatility. Trading volume reached approximately 154,000 shares, elevated compared to the average of around 60,000-70,000.

Analysts expect Q1 2026 revenue of $3.00 billion, up 8% from $2.77 billion in the year-ago quarter. Consensus earnings per share (EPS) estimate stands at $4.31, reflecting steady profitability from the cystic fibrosis (CF) portfolio.

Revolution Medicines (RVMD) stock surged +41% over the past 30 days, primarily driven by positive topline results from a pancreatic cancer trial announced mid-period. The stock experienced high volatility with a sharp spike followed by consolidation, reflecting investor enthusiasm for clinical progress.

CBIO shares plunged 29.3% to $15.81 from the previous close of $22.37 during today's trading session. Primary catalyst: Profit-taking and digestion of Q1 earnings reported on April 29, which showed an EPS loss of $0.70 beating consensus estimates of -$0.79 but highlighted ongoing cash burn despite a strong $189.2 million cash position.

SMMT shares fell approximately 20% in premarket trading on Friday, May 1, 2026, dropping from a prior close of approximately $20.83 to around $16.66. The primary catalyst was the HARMONi-3 interim PFS analysis miss, with the Phase III global trial failing to meet expectations for its squamous cohort, undermining the ivonescimab thesis.

Analysts expect Q1 2026 revenue of around $224 million, a significant increase from $108 million in Q1 2025. Consensus EPS forecast points to a loss of approximately $2.29 per share, potentially improved from prior quarters.

Shares of Regeneron Pharmaceuticals (REGN) are down approximately 6% on Wednesday, trading near $688 after closing at $731.77 on April 28, in an earnings-driven selloff despite a headline beat on both EPS and revenue. Primary catalyst: A sharp "beat and sell" market reaction driven by the continued deterioration of the core EYLEA franchise — total U.S. EYLEA HD and EYLEA net sales declined 10% year-over-year to $941 million, more than offsetting record Dupixent growth.

ERAS shares are down approximately 47.26% in Tuesday's session, falling from a prior close of $19.15 to approximately $10.10 intraday. The primary catalyst is the disclosure of a treatment-related patient death buried within the otherwise positively framed preliminary Phase 1 data release for lead drug candidate ERAS-0015.

CMPX shares are plunging approximately 62% in Monday's session, collapsing to roughly $1.98 from a prior close of $5.21 on April 24, 2026. The primary catalyst is the presentation of topline secondary endpoint data from the Phase 2/3 COMPANION-002 trial of tovecimig (CTX-009) plus paclitaxel in advanced biliary tract cancer, widely interpreted as disappointing.

Shares experienced a sharp decline of over 50% following interim Phase 1 data for obesity drug WVE-007, as results underwhelmed versus high expectations. Analysts retain a Strong Buy consensus with an average price target near $28, implying substantial upside potential.

MPLT exhibits an overall uptrend since its IPO, with shares surging approximately 78% over the past month amid high volatility. Short-term price action shows consolidation below key moving averages, with recent pullback from highs near $32.

vTv Therapeutics (VTVT) stock rose +12% over the past 30 days, driven by positive analyst coverage and participation in industry conferences. Over the past quarter, shares gained +19%, supported by an earnings beat, milestone funding from partnerships, and ongoing Phase 3 trial progress.

Shares of IOVA are declining approximately 6.49% in Wednesday's session on April 22, 2026, falling from a prior close of $3.70 to approximately $3.46, as broad biotech sector selling pressure and risk-off sentiment weigh on commercial-stage but unprofitable biopharmaceutical companies.